

Paper No. \_\_\_\_\_

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

BIODELIVERY SCIENCES INTERNATIONAL, INC.  
Petitioner

v.

RB PHARMACEUTICALS LIMITED  
Patent Owner

Patent 8,475,832

---

Mailed: June 20, 2014

---

**PETITION FOR *INTER PARTES* REVIEW  
UNDER 35 USC §§ 311-319 AND 37 CFR § 42.100 *ET. SEQ.***

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION.....	1
II. MANDATORY NOTICES AND CERTIFICATIONS .....	2
III. SUMMARY OF THE ‘832 PATENT AND PROSECUTION .....	5
A. The film formulation of ‘832 patent presented no particular challenge .....	5
B. The invention disclosed in the ‘832 patent is not surprising .....	11
C. The ‘832 patent was allowed in a haze of confusing definitions and incorrect arguments.....	13
D. The alleged novelty of the challenged claims is contradicted by the ‘832 patent specification.....	15
E. The Patent Office has finally rejected claims that are narrower than challenged claim 15 .....	17
IV. CONSTRUCTION OF THE CHALLENGED CLAIMS.....	21
A. Construction of “film formulation.” .....	22
B. Construction of “provides an in vivo plasma profile.” .....	26
V. STATEMENT OF PRECISE RELIEF REQUESTED AND CLAIM-BY-CLAIM EXPLANATION OF GROUNDS OF INVALIDITY .....	30
A. The only claim elements entitled to patentable weight in the challenged claims are found in the admitted prior art and additional art cited herein.....	30
B. The wherein clause, which recites a desired result, is not entitled to patentable weight.....	31
C. Even if the desired result were entitled to patentable weight, it is still anticipated by and obvious in view of the cited art.....	32
Ground 1. Claims 15-19 are obvious over <i>Euro-Celtique</i> .....	34
Ground 2. Claims 15-19 are obvious over <i>Euro-Celtique</i> in view of the <i>EMEA Study Report</i> .....	44

Ground 3.	Claims 15-19 are obvious over <i>Euro-Celtique</i> in view of the <i>EMEA Study Report</i> and WO 03/030883 .....	48
Ground 4.	Claims 15-19 are obvious over <i>Euro-Celtique</i> in view of the <i>EMEA Study Report</i> and <i>Yang</i> .....	51
VII. CONCLUSION .....		55

Exhibit List

- Exhibit 1001: US Patent 8,475,832 (“**832 Patent**”)
- Exhibit 1002: *Reckitt Benckiser Pharmaceuticals, Inc., RB Pharmaceuticals Limited, and MonoSol, RX, LLC.*, EDNC Civil Action No. 5:13-cv-760, Complaint filed October 29, 2013 (“**Complaint**”)
- Exhibit 1003: Reckitt 2012 Annual Report (“**Annual Report**”)
- Exhibit 1004: Declaration of Maureen Reitman, Sc.D. (“**Reitman Decl.**”)
- Exhibit 1005: Declaration of Phillip T. Lavin, Ph.D. (“**Lavin Decl.**”)
- Exhibit 1006: First Office Action mailed August 31, 2011 (“**First OA**”)
- Exhibit 1007: Response filed February 29, 2012 (“**First Response**”)
- Exhibit 1008: Second Office Action mailed May 2, 2012 (“**Second OA**”)
- Exhibit 1009: Response to filed October 22, 2012 (“**Second Response**”)
- Exhibit 1010: Third Office Action mailed November 6, 2012 (“**Third OA**”)
- Exhibit 1011: Response to filed April 30, 2013 (“**Third Response**”)
- Exhibit 1012: Notice of Allowance mailed May 24, 2013, including the attached Interview Summary (“**NOA**”)
- Exhibit 1013: Suboxone® tablet label, Revised September 2006 (“**Suboxone Tablet Label**”)
- Exhibit 1014: Excerpt from MERRIAM-WEBSTER’S COLLEGIATE DICTIONARY, 10<sup>TH</sup> ED., Merriam-Webster, Inc. (2000)
- Exhibit 1015: European Medicines Agency (EMA) Study Report on Suboxone® tablets, 2006 (“**EMA Study Report**”)
- Exhibit 1016: US Patent No. 7,357,891, published December 23, 2004 and issued April 15, 2008, to Yang *et al.* (“**Yang**”)

- Exhibit 1017: International Patent Publication No. WO 2008/040534, published April 10, 2008, to Applicant Labtec GmbH (“*Labtec*”)
- Exhibit 1018: International Patent Publication No. WO 2008/025791, published March 6, 2008, to Applicant Euro-Celtique S.A. (“*Euro-Celtique*”)
- Exhibit 1019: US Patent Publication No. 2005/0085440, published April 21, 2005, to Birch *et al.* (“*Birch*”)
- Exhibit 1020: Power of Attorney
- Exhibit 1021: Assignment from Reckitt Benckiser Healthcare (UK) Limited to RB Pharmaceuticals Limited
- Exhibit 1022: Assignment from MonoSol Rx, LLC to Reckitt Benckiser Healthcare (UK) Limited
- Exhibit 1023: US Patent No. 7,425,292, published June 12, 2003 and issued September 16, 2008, to Yang *et al.* (“*292 patent*”)
- Exhibit 1024: M.Voet, THE GENERIC CHALLENGE (Brown Walker Press 2d ed. 2008)
- Exhibit 1025: Dismissal of Complaint, EDNC Civil Action No. 5:13-cv-760, May 21, 2014
- Exhibit 1026: US Patent Application No. 13/964,975, published on Jan. 2, 2014 as US Patent Publication No. US2014/0005218
- Exhibit 1027: Office Action in US Patent Application No. 13/964,975, dated November 7, 2013
- Exhibit 1028: Amendment and Response to Office Action in US Patent Application No. 13/964,975, dated Jan. 2, 2014
- Exhibit 1029: Office Action in US Patent Application No. 13/964,975, dated March 7, 2014
- Exhibit 1030: International Patent Publication No. WO 2005/079750, “Films

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.